The head of the Food and Drug Administration has called for a wide-ranging federal investigation into the approval of Biogen’s treatment for …
Storyboard
FDA to Probe How It Approved Biogen's Controversial Alzheimer's Drug
The head of the Food and Drug Administration is calling for an investigation into how her agency approved Biogen's Aduhelm, the first drug to treat Alzheimer's Disease in nearly two decades. This despite failing to receive an endorsement from an independent panel of experts, who said there was inconclusive evidence of the drug's efficacy. Recently, another panel ruled Aduhelm shows no benefit, and major U.S. hospitals and insurers have already declined to prescribe it.
An expert panel unanimously voted that Biogen’s controversial Alzheimer’s drug does not provide more benefit to patients than supportive care. The latest blow dealt to Aduhelm comes in the same week that two major health centers said they will not carry the drug. The Institute for Clinical and …
Acting Food and Drug Administration Commissioner Dr. Janet Woodcock on Wednesday pushed back against questions from a journalist about the …
July 15 (Reuters) - Biogen Inc's (BIIB.O) Alzheimer's drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare. An …
FDA statisticians did not believe experimental Alzheimer's treatment Aduhelm proved that it could slow down the cognitive disease, but the top brass …
A Biogen rep said assessing its drug requires "innovative thinking." Biogen's new Alzheimer's drug Aduhelm continues to face opposition after its …
CNN — Two House committees have launched an investigation into the approval and pricing of the Alzheimer’s disease drug aducanumab, made by the company Biogen and sold under the brand name Aduhelm. The US Food and Drug Administration approved the drug earlier this month under its “accelerated …
Washington (AFP) – The US drug regulator on Thursday said only people with mild dementia should receive the first new Alzheimer's medicine in decades, after facing intense backlash from many in the medical community over its authorization. Biogen's Aduhelm received an "accelerated approval" by the …
The eye-popping $56,000 price tag on Biogen’s newly approved Alzheimer’s medication has generated significant debate on the value of a drug not yet proven to slow the mind-robbing disease. But Aduhelm's price is only the start of what consumers and insurers might pay to get the first new Food and …
The US Food and Drug Administration (FDA) approval yesterday of the first new drug for Alzheimer’s disease in 18 years was welcomed by some people …
Further Reading
Learn more about Biogen's Alzheimer's Drug along with other innovations in health and medicine.
Storyboard
